Analystreport

Mirum Pharmaceuticals (NASDAQ: MIRM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report